Condition

Relapsed or Refractory Multiple Myeloma clinical trials and research

• 14Clinical trials
• 30Countries

Newest Relapsed or Refractory Multiple Myeloma clinical trials

All recruiting trials (14)

• AZD4045 in Relapsed or Refractory Multiple Myeloma

  This study tests AZD4045 alone and with daratumumab and aldesleukin in adults whose multiple myeloma has returned or stopped responding to treatment.

  Recruiting at 3 sites Phase 1/2 AstraZeneca · Duarte, California and 11 other locations · NCT07681596

• A new treatment approach for relapsed or refractory multiple myeloma in adults

  This study tests if IBI3003 works better than the investigator's choice treatment for adults whose multiple myeloma has returned or persisted after prior therapy.

  Recruiting Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Shanghai, Shanghai Municipality · NCT07623798

• O&D-001 CAR‑T injection for relapsed or refractory multiple myeloma

  This trial will test a CAR‑T injection called O&D‑001 that targets BCMA and GPRC5D in adults with relapsed or refractory multiple myeloma who have had at least two prior therapies.

  Recruiting Phase 1 O&D BioTech Group CO., Limited · Guangzhou, Guangdong · NCT07369895

• F182112 given with other drugs for relapsed or refractory multiple myeloma

  This trial will test whether F182112, given with different drug regimens, helps people whose multiple myeloma has returned or stopped responding to prior treatments.

  Recruiting Phase 2 Shandong New Time Pharmaceutical Co., LTD · Tianjin · NCT07312188

• QLS32015 versus pomalidomide+dexamethasone or selinexor+dexamethasone for relapsed or refractory multiple myeloma

  This will see if QLS32015 alone controls disease and is safe compared with pomalidomide+dexamethasone or selinexor+dexamethasone in adults with relapsed or refractory multiple myeloma who have had at least three prior treatments.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07138209

• mRNA-2808 for relapsed or refractory multiple myeloma

  This will test whether mRNA-2808 is safe and tolerable for people with relapsed or refractory multiple myeloma who have already received standard therapies.

  Recruiting at 10 sites Phase 1/2 ModernaTX, Inc. · Birmingham, Alabama and 9 other locations · NCT07116616

• QLS32015 combination therapy for relapsed or refractory multiple myeloma

  This study will test whether the injected drug QLS32015 combined with approved myeloma medicines helps people whose multiple myeloma has come back or not responded to previous treatment.

  Recruiting Phase 2 Qilu Pharmaceutical Co., Ltd. · Tianjin · NCT07018050

• Testing YKST02 for patients with relapsed or refractory multiple myeloma

  This study is testing a new treatment called YKST02 to see if it can help people with relapsed or hard-to-treat multiple myeloma by boosting their immune system.

  Recruiting at 7 sites Phase 1 Excyte Biopharma Ltd · Beijing, Beijing Municipality and 11 other locations · NCT06574568

• Evaluating SIM0500 for patients with relapsed or refractory multiple myeloma

  This study is testing a new drug called SIM0500 to see if it can help adults with relapsed or refractory multiple myeloma who haven't had success with other treatments.

  Recruiting at 16 sites Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Phoenix, Arizona and 15 other locations · NCT06375044

• Evaluating MBS314 for patients with relapsed or refractory multiple myeloma

  This study is testing a new treatment called MBS314 to see if it can help people with relapsed or refractory multiple myeloma feel better.

  Recruiting Phase 1/2 Beijing Mabworks Biotech Co., Ltd. · Beijing · NCT06232096

• Evaluating a new combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of two treatments for people with relapsed or refractory multiple myeloma to see if it's safe and how well it works.

  Recruiting at 14 sites Phase 1 Genentech, Inc. · Camperdown, New South Wales and 13 other locations · NCT05927571

• Testing JNJ-79635322 for patients with advanced multiple myeloma or AL amyloidosis

  This study is testing a new drug called JNJ-79635322 to see how much of it is safe to give to people with advanced multiple myeloma or AL amyloidosis who haven't responded to other treatments.

  Recruiting at 25 sites Phase 1 Janssen Research & Development, LLC · Duarte, California and 28 other locations · NCT05652335

• Evaluating a new antibody drug for treating relapsed or refractory multiple myeloma

  This study is testing a new antibody drug called STI-6129 to see if it can help people with relapsed or refractory multiple myeloma feel better and improve their treatment outcomes.

  Recruiting at 4 sites Phase 1/2 Zhejiang ACEA Pharmaceutical Co. Ltd. · Beijing, Beijing Municipality and 3 other locations · NCT05565807

• Comparing two treatment combinations for relapsed or refractory multiple myeloma

  This study is testing whether a new combination of mezigdomide, bortezomib, and dexamethasone works better than another combination for people with relapsed or refractory multiple myeloma who have already tried some treatments.

  Recruiting at 42 sites Phase 3 Celgene · Los Alamitos, California and 265 other locations · NCT05519085

Related topics

Quick answers

How many Relapsed or Refractory Multiple Myeloma clinical trials are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in China (10 trials), United States (5 trials), Australia (3 trials), Belgium (2 trials), France (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 5, Phase 1/2: 4, Phase 3: 3, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →